OTCM
MDXXF
Market cap6mUSD
Jun 10, Last price
0.08USD
Name
Pharmala Biotech Holdings Inc
Chart & Performance
Profile
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY |
---|---|---|---|---|
2024‑08 | 2023‑08 | 2022‑08 | 2021‑08 | |
Income | ||||
Revenues | 1,035 94.60% | 532 581.44% | 78 | |
Cost of revenue | 1,473 | 1,063 | 1,052 | |
Unusual Expense (Income) | ||||
NOPBT | (438) | (531) | (973) | |
NOPBT Margin | ||||
Operating Taxes | (3) | |||
Tax Rate | ||||
NOPAT | (438) | (531) | (973) | |
Net income | (824) 5.61% | (780) -20.88% | (986) -60.72% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 697 | 189 | ||
BB yield | ||||
Debt | ||||
Debt current | 254 | (372) | ||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (419) | 58 | (1,224) | |
Cash flow | ||||
Cash from operating activities | (321) | (340) | (625) | |
CAPEX | (226) | (995) | ||
Cash from investing activities | (226) | (507) | (995) | |
Cash from financing activities | 772 | 189 | ||
FCF | (498) | (468) | (975) | |
Balance | ||||
Cash | 419 | 195 | 852 | |
Long term investments | ||||
Excess cash | 368 | 168 | 848 | |
Stockholders' equity | 739 | 1,007 | 1,527 | |
Invested Capital | 1,614 | 1,469 | 686 | |
ROIC | ||||
ROCE | ||||
EV | ||||
Common stock shares outstanding | 88,574 | 84,527 | 82,999 | |
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (367) | (479) | (961) | |
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT |